Kinfo
Taysha Gene Therapies Inc. logo

Taysha Gene Therapies Inc.

TSHANASDAQHealthcare·US · USD
$6.73
+0.39 (+6.15%)
Live · 2026-06-29

Price

Key statistics

Valuation
Market cap1.82B USD
Enterprise value1.61B USD
Trailing P/E2.53
Forward P/E-14.41
PEG ratio0.05
Price / sales243.86
Price / book8.59
Profitability
Gross margin0.00%
Operating margin-1774.37%
Profit margin0.00%
Return on assets-37.77%
Return on equity-97.28%
Income (TTM)
Revenue7.47M USD
Gross profit7.47M USD
EBITDA-131.41M USD
Net income-129.88M USD
Diluted EPS-$0.38
Rev. growth (YoY)-100.00%
Balance sheet
Total cash276.58M USD
Total debt68.55M USD
Debt / equity32.34
Current ratio14.04
Book value / share$0.74
Cash flow (TTM)
Operating cash flow-111.95M USD
Levered free cash flow-73.45M USD
Shares & price
Shares outstanding287.28M
Float196.74M
Held by institutions86.05%
Beta1.18
50-day MA$6.13
200-day MA$4.97
52-week high$7.30
52-week low$2.25
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-05-212.603.64+40.00%2026-05-06-0.10-0.11−10.00%2026-03-19-0.10-0.07+30.00%2025-11-04-0.09-0.09+0.00%2025-10-222.632.68+1.90%
About Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc. is a biotechnology company specializing in the development of transformative gene therapy treatments for central nervous system (CNS) diseases. The company is at the forefront of employing advanced gene therapy techniques to address rare, debilitating neurological conditions that lack effective treatment options. Taysha Gene Therapies is committed to leveraging its expertise in gene therapy to create long-term, potentially curative solutions that improve patient outcomes. It collaborates with academic institutions and utilizes strategic partnerships to facilitate the advancement and commercialization of its pipeline. Through targeted delivery systems and innovative genetic approaches, Taysha focuses on various therapeutic candidates, aiming to address a wide spectrum of CNS disorders. Positioned prominently in the biotechnology sector, the company plays a significant role in advancing the field of genetic medicine, offering hope for patients with limited options. Its contributions help to shape the future of precision medicine, marking a pivotal shift in the treatment landscape for genetic disorders.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Sean P. Nolan
Employees
99
Headquarters
Dallas, TX, United States

Frequently asked questions about Taysha Gene Therapies Inc.